318 related articles for article (PubMed ID: 25224783)
1. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
[TBL] [Abstract][Full Text] [Related]
2. A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.
Strijbis VJF; Romano LGR; Cheung KL; Eikenboom J; Liu YP; McCreary AC; Leebeek FWG; Bos MHA
J Thromb Haemost; 2023 Jun; 21(6):1466-1477. PubMed ID: 36863564
[TBL] [Abstract][Full Text] [Related]
3. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.
Milanov P; Ivanciu L; Abriss D; Quade-Lyssy P; Miesbach W; Alesci S; Tonn T; Grez M; Seifried E; Schüttrumpf J
Blood; 2012 Jan; 119(2):602-11. PubMed ID: 22031860
[TBL] [Abstract][Full Text] [Related]
4. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
5. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Girard TJ; Lasky NM; Grunz K; Broze GJ
J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
[TBL] [Abstract][Full Text] [Related]
6. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
[TBL] [Abstract][Full Text] [Related]
7. Platelet and endothelial expression of clotting factors for the treatment of hemophilia.
Montgomery RR; Shi Q
Thromb Res; 2012 May; 129 Suppl 2(Suppl 2):S46-8. PubMed ID: 22421106
[TBL] [Abstract][Full Text] [Related]
8. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
9. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
10. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
11. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
12. Coagulation factors with improved properties for hemophilia gene therapy.
Pipe SW
Semin Thromb Hemost; 2004 Apr; 30(2):227-37. PubMed ID: 15118934
[TBL] [Abstract][Full Text] [Related]
13. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for hemophilia.
Lynch CM
Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
[TBL] [Abstract][Full Text] [Related]
15. Factor IX mutants with enhanced catalytic activity.
Hartmann R; Dockal M; Kammlander W; Panholzer E; Nicolaes GA; Fiedler C; Rosing J; Scheiflinger F
J Thromb Haemost; 2009 Oct; 7(10):1656-62. PubMed ID: 19656280
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for the hemophilias.
VandenDriessche T; Collen D; Chuah MK
J Thromb Haemost; 2003 Jul; 1(7):1550-8. PubMed ID: 12871290
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy for Hemophilia.
Nienhuis AW; Nathwani AC; Davidoff AM
Mol Ther; 2017 May; 25(5):1163-1167. PubMed ID: 28411016
[TBL] [Abstract][Full Text] [Related]
18. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
19. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
20. Gene-based continuous expression of FVIIa for the treatment of hemophilia.
Margaritis P
Front Biosci (Schol Ed); 2012 Jan; 4(1):287-99. PubMed ID: 22202061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]